



08 November 2018

ASX Limited
20 Bridge Street
Sydney NSW 2000

COMPANY ANNOUNCEMENTS

RESULTS OF THE ANNUAL GENERAL MEETING OF MEMBERS

In accordance with Listing Rule 3.13.2, Cellmid Limited (**ASX: CDY**) advises that the resolutions put to the Annual General Meeting of Shareholders held on Thursday 8 November 2018, were passed by the requisite majority.

All resolutions were passed unanimously on a show of hands.

Please find attached the information required pursuant to Section 251AA of the Corporations Act 2001 (Cth) and Listing Rule 3.13.2.

END

Company Maria Halasz, CEO Cellmid T +612 9221 6830	Investor Relations & Media Rebecca Wilson WE Buchan T + 61 417 382 391 rwilson@we-buchan.com
--	--

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lynamid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining to this novel target is being exploited through wholly owned subsidiaries Lynamid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia and Japan, and currently expanding distribution in other territories. For further information, please see www.cellmid.com.au and www.myevolis.com.au

Midkine (MK)

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, midkine is only evident in a disease context, and targeting midkine is not expected to harm normal healthy tissues.

Investment in life sciences companies

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.

DISCLOSURE OF MEETING PROXY VOTES

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	PROXY'S DISCRETION	ABSTAIN	FOR	AGAINST	ABSTAIN
RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT	S	24,537,395	21,261,743 (86.65%)	3,155,017 (12.86%)	120,635 (0.49%)	349,637	N/A	N/A	N/A
RESOLUTION 2 – RE-ELECTION OF DR DAVID KING AS DIRECTOR	S	34,211,646	31,298,240 (91.48%)	2,792,771 (8.16%)	120,635 (0.35%)	5,746	N/A	N/A	N/A
RESOLUTION 3 – APPROVAL TO INCREASE THE MAXIMUM AGGREGATE AMOUNT OF DIRECTORS' FEES	S	24,849,374	20,631,592 (83.03%)	4,022,147 (16.19%)	195,635 (0.79%)	37,658	N/A	N/A	N/A
RESOLUTION 4 – APPROVAL OF ISSUE OF INCENTIVE SHARES TO MARIA HALASZ	S	32,361,084	27,572,811 (85.20%)	4,668,438 (14.43%)	119,835 (0.37%)	9,500	N/A	N/A	N/A
RESOLUTION 5 – APPROVAL OF ISSUE OF DIRECTOR FEE SHARES TO DENNIS ECK	S	28,827,017	26,201,576 (90.89%)	2,505,606 (8.69%)	119,835 (0.42%)	58,796	N/A	N/A	N/A